A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation

被引：0
|
作者：
Ocio, Enrique M.
Bringhen, Sara
Oliva, Stefania
Rodriguez-Otero, Paula
Kanagavel, Dheepak
Oprea, Corina
Wei, Vivian
Doroumian, Severine
Martinez-Lopez, Joaquin
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3160
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant
    Ocio, Enrique M.
    Rodriguez Otero, Paula
    Bringhen, Sara
    Oliva, Stefania
    Nogai, Axel
    Attal, Michel
    Moreau, Philippe
    Kanagavel, Dheepak
    Fitzmaurice, Thomas F.
    Wu, Junlong
    Martinez Lopez, Joaquin
    BLOOD, 2018, 132
  • [2] Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
    Crusoe, Edvan De Queiroz
    Higashi, Fabiana
    Martinez, Gracia
    Bittencourt, Rosane
    Pinto Neto, Jorge Vaz
    Sousa, Lais
    Santucci, Rodrigo
    Pessoa Magalhaes, Roberto Jose
    Colli, Gilberto
    Marques Nunes, Renata Ferreira
    Ribeiro, Glaciano
    Nicacio, Jandir
    Zanella, Karla Richter
    Kutner, Jose Mauro
    Magalhaes, Andre
    Leao, Danielle
    Hallack Neto, Abrahao Elias
    Braga, Walter
    Souza, Emanuella G.
    Guimaraes, Antonio Julio A. M.
    Durigon, Giovanna Steffenello
    Laks, Dani
    Maiolino, Angelo
    de Moraes Hungria, Vania Tietsche
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2020, 42 (02) : 118 - 124
  • [3] Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma
    Figueiredo, A.
    Atkins, H.
    Mallick, R.
    Kekre, N.
    Kew, A.
    McCurdy, A.
    CURRENT ONCOLOGY, 2020, 27 (02) : E81 - E85
  • [4] A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment
    Terpos, Evangelos
    Kastritis, Efstathios
    Symeonidis, Argiris
    Pouli, Anastasia
    Delimpasi, Sosana
    Katodritou, Eirini
    Hatzimichael, Eleftheria
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Theodorakakou, Foteini
    Spiliopoulou, Vasiliki
    Syrigou, Rodanthi
    Eleutherakis-Papaiakovou, Evangelos
    Manousou, Kyriaki
    Gavriatopoulou, Maria
    Dimopoulos, Meletios A.
    BLOOD, 2023, 142
  • [5] A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
    Figueiredo, Amarilis
    Atkins, Harold
    Mallick, Ranjeeta
    Kekre, Natasha
    Kew, Andrea
    McCurdy, Arleigh
    BLOOD, 2016, 128 (22)
  • [6] Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
    Ocio, Enrique M. M.
    Bringhen, Sara
    Martinez-Lopez, Joaquin
    San-Miguel, Jesus
    Oliva, Stefania
    Rodriguez-Otero, Paula
    Le Roux, Nadia
    Dong, Yvonne
    Doroumian, Severine
    Mace, Sandrine
    Mateos, Maria-Victoria
    HEMASPHERE, 2023, 7 (02):
  • [7] Pembrolizumab Added to First-Line Cyclophosphamide, Bortezomib and Dexamethasone in Newly Diagnosed Transplant Non-Eligible Myeloma Patients: A Phase 2A Open Label, Multi Centre Study
    Kotb, Rami
    Gul, Engin
    Abdel-Samad, Nizar
    Othman, Ibraheem
    Pavic, Michel
    Reece, Donna E.
    BLOOD, 2021, 138
  • [8] Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma
    Tsukada, Nobuhiro
    Ikeda, Masahiro
    Shingaki, Sumito
    Miyazaki, Kanji
    Meshitsuka, Sosuke
    Abe, Yu
    Yoshiki, Yumiko
    Suzuki, Kenshi
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S205 - S205
  • [9] Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA)
    Roussel, Murielle
    Moreau, Philippe
    Hebraud, Benjamin
    Laribi, Kamel
    Jaccard, Arnaud
    Dib, Mamoun
    Slama, Borhane
    Dorvaux, Veronique
    Royer, Bruno
    Frenzel, Laurent
    Zweegman, Sonja
    Klein, Saskia K.
    Broijl, Annemiek
    Jie, Kon-Siong
    Wang, Jianping
    Vanquickelberghe, Veronique
    Boer, Carla de
    Kampfenkel, Tobias
    Gries, Katharine S.
    Fastenau, John
    Sonneveld, Pieter
    LANCET HAEMATOLOGY, 2020, 7 (12): : E874 - E883
  • [10] Bortezomib-lenalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation: A single center experience
    Kaloyannidis, P.
    Abduljalil, O.
    Abdulbaqi, M.
    Jatham, A.
    Estanislao, A.
    Raslan, H.
    Moinuddin, A.
    Apostolidis, J.
    Al Sagheir, A.
    Al Hashmi, H.
    Al Anazi, K.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S462 - S462
12345